新型抗雄药物对比多西他赛治疗转移性激素敏感性前列腺癌:网络荟萃分析
该网络荟萃分析依据PRISMA与PICO方法系统评价转移性激素敏感性前列腺癌一线随机对照试验,发现无治疗在总生存上优于多西他赛,但阿比特龙、恩扎卢胺、阿帕他胺均显著降低疾病进展率,且恩扎卢胺与阿帕他胺的高级别不良事件率显著更低。
要点
- 无治疗在总生存上显著优于多西他赛。
- 阿比特龙、恩扎卢胺、阿帕他胺均显著降低疾病进展风险。
- 恩扎卢胺与阿帕他胺的高级别不良事件率显著低于多西他赛。
核心结论
- 雄激素受体轴靶向治疗联合雄激素剥夺治疗对比多西他赛未在总生存上显示统计学显著优势。
- 该联合治疗与更低的疾病进展率相关,且阿帕他胺与恩扎卢胺安全性更好。
研究设计与样本
- 系统综述与网络荟萃分析,遵循PRISMA标准与PICO方法,纳入转移性激素敏感性前列腺癌一线治疗的随机对照试验。
主要发现
- 总生存:阿比特龙HR 0.89(95%CI 0.76-1.05)、恩扎卢胺HR 0.90(95%CI 0.69-1.19)、阿帕他胺HR 0.90(95%CI 0.67-1.22),均未达统计学显著。
- 疾病进展:阿比特龙HR 0.71(95%CI 0.59-0.86)、恩扎卢胺HR 0.61(95%CI 0.49-0.75)、阿帕他胺HR 0.74(95%CI 0.57-0.95),均显著低于多西他赛。
- 高级别不良事件:阿比特龙OR 0.83(95%CI 0.56-1.21)未达显著;恩扎卢胺OR 0.56(95%CI 0.35-0.92)、阿帕他胺OR 0.44(95%CI 0.24-0.79)显著更低。
临床怎么用
- 对于转移性激素敏感性前列腺癌,雄激素受体轴靶向治疗联合ADT可延缓疾病进展,恩扎卢胺与阿帕他胺的高级别不良事件风险更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Docetaxel represent the standard of care in patients with metastatic, hormone sensitive prostate cancer. However, androgen receptor axis targeted therapies have also been shown to be effective. We aimed to analyze findings in randomized controlled trials investigating first-line treatment for hormone sensitive prostate cancer. MATERIALS AND METHODS: We systematically reviewed the literature according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the PICO (Population, Intervention, Comparator, Outcomes) methodology. Outcomes of interest were overall and progression-free survival, and the rate of high grade adverse events. RESULTS: No treatment was superior to docetaxel in terms of overall survival. However, abiraterone (HR 0.89, 95% CI 0.76-1.05), enzalutamide (HR 0.90, 95% CI 0.69-1.19) and apalutamide (HR 0.90, 95% CI 0.67-1.22) showed nonstatistically significant lower overall mortality rates than docetaxel. Abiraterone (HR 0.71, 95% CI 0.59-0.86), enzalutamide (HR 0.61, 95% CI 0.49-0.75) and apalutamide (HR 0.74, 95% CI 0.57-0.95) also showed statistically significant lower disease progression rates than docetaxel. Furthermore, abiraterone (OR 0.83, 95% CI 0.56-1.21) showed no statistically significant lower rate of high grade adverse events compared to docetaxel. Finally, enzalutamide (OR 0.56, 95% CI 0.35-0.92) and apalutamide (OR 0.44, 95% CI 0.24-0.79) showed statistically significant lower rates of high grade adverse events compared to docetaxel. CONCLUSIONS: Treatment with androgen receptor axis targeted therapies combined with androgen deprivation therapy in patients with hormone sensitive prostate cancer did not offer a statistically significant advantage in overall survival compared to the standard, docetaxel. However, it was associated with a lower disease progression rate. Moreover, apalutamide and enzalutamide offer a better safety profile.
引用
- Marchioni M, Di Nicola M, Primiceri G, et al. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. J Urol. 2019. PMID: 31689158. doi:10.1097/JU.0000000000000636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。